Skip to content

Synlico

2 viewers · 30d

Total raised

$3.0M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $3.0M
ROUNDS
1
INVESTORS
1
FOUNDED
2021
HQ
South San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Synlico Inc. is an AI-powered drug discovery company dedicated to transforming traditional approaches in oncology through the development of engineered T cell therapies tailored to combat solid tumors. By harnessing advanced computational techniques, Synlico leads a paradigm shift in understanding and addressing the complexities of cellular behavior in the tumor microenvironment.

What sets it apart

Synlico stands out for its innovative integration of causality into drug design, enabling the engineering of therapies that are both more effective and tailored to the unique characteristics of individual patients' tumors.

Funding history

1 round
Equity+2Feb 24, 2025
Form D
+$3.0M$3.0M total

Latest SEC filings

via EDGAR · CIK 0001880583
Form D · Feb 24, 2025View on EDGAR

Products

1 tracked

CausalCell AI

Oncology / Drug Discovery

CausalCell AI is a computational technology platform that utilizes single-cell bioinformatics combined with machine learning and causal discovery methodologies. This advanced platform provides invaluable insights into the tumor microenvironment, enhancing the ability to develop targeted T cell therapies.

  • Detailed analysis of tumor microenvironment heterogeneity
  • Patient reclassification based on shared tumor microenvironment signatures
  • Identification of causal relationships between T cell intracellular elements and their functional outcomes in patients